Telix Pharmaceuticals Limited (TLX) generates a steady flow of news related to its radiopharmaceutical pipeline, commercial portfolio, and global operations. As a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, its announcements often highlight progress in oncology and rare disease programs, regulatory milestones, and commercial performance.
Recent Telix news has covered precision medicine portfolio updates, including Phase 3 data for TLX591-CDx (Illuccix) in China, regulatory interactions for TLX101-CDx (Pixclara) and TLX250-CDx (Zircaix) with the U.S. Food and Drug Administration, and inclusion of TLX250-CDx in international renal imaging guidelines. The company also reports on clinical collaborations, such as its agreement with Varian to explore combining Telix’s theranostic products with external beam radiation therapy.
Investors and clinicians following TLX news can expect updates on clinical trial milestones (for example, first patient dosed in the SOLACE trial for TLX090 or in the BiPASS Phase 3 trial for prostate cancer diagnosis), as well as information on reimbursement and market access developments. Telix has announced CMS Transitional Pass-Through status and a permanent HCPCS code for Gozellix in the United States, along with country-level approvals and launches for Illuccix in Europe and the United Kingdom.
Telix also issues news on financial performance and guidance, such as quarterly revenue updates and full-year revenue outlook, and on participation in major healthcare conferences where management presents the company’s pipeline and commercial strategy. For users tracking TLX, the news stream provides insight into how Telix advances its radiopharmaceutical products from clinical development through regulatory review and commercialization across multiple regions.
Telix Pharmaceuticals (NASDAQ: TLX) has initiated its Phase 3 BiPASS clinical trial by dosing the first patient, aiming to expand indications for Illuccix® and Gozellix® in prostate cancer diagnosis. The study will evaluate if combining MRI and PSMA-PET imaging can improve diagnostic accuracy and potentially help patients avoid unnecessary biopsies.
The trial will enroll 204 patients across Australia and the United States. The study builds upon promising research from PRIMARY and PRIMARY2 studies, which demonstrated benefits of combined imaging approaches. If successful, this could expand Telix's U.S. market for PSMA-PET imaging agents by approximately 800,000 scans, addressing a significant clinical need given that up to 75% of current prostate biopsies are negative.
Telix Pharmaceuticals (NASDAQ: TLX) announced its participation in two upcoming healthcare investment conferences. CEO Dr. Christian Behrenbruch will participate in fireside chats at the Morgan Stanley Global Healthcare Conference on September 8, 2025, at 4:50 p.m. ET and the H.C. Wainwright Global Investment Conference on September 9, 2025, at 12:00 p.m. ET.
Both conferences will be held in New York, with sessions available via live webcast and on-demand through the company's investor relations website.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) reported strong H1 2025 financial results, with revenue surging 63% to $390.4 million. The company achieved an Adjusted EBITDA of $21.1 million despite increased operating expenditure from strategic acquisitions and R&D investments.
Key highlights include a group gross profit margin of 53%, R&D investment of $81.6 million (up 47% YoY), and positive operating cash flow of $17.7 million. The Precision Medicine segment saw 30% revenue growth, while RLS Radiopharmacies contributed $109.5 million in revenue. The company maintains its FY 2025 revenue guidance of $770-800 million.
Telix achieved significant pipeline milestones, including completion of Phase 3 enrollment for TLX591 in prostate cancer and regulatory approvals for multiple therapeutic programs.
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has announced it will release its financial results for H1 2025 on August 21, 2025. The company will host an investor webcast and conference call at 9:30 AM AEST (7:30 PM EDT on August 20, 2025) to discuss the results.
Investors can access the presentation through a webcast link or join via teleconference, with registration required for both options.
Telix Pharmaceuticals (NASDAQ: TLX) reported strong Q2 2025 financial results with unaudited group revenue of $204 million, representing a 63% year-over-year increase. The company reaffirmed its FY 2025 revenue guidance of $770-800 million.
Key highlights include the U.S. launch of Gozellix® with a Level II HCPCS code assignment, and significant progress in the ProstACT™ Global Phase 3 trial with all 30 patients consented for Part 1. Global Illuccix® revenue reached $154 million, up 25% year-over-year, while RLS revenue contributed $46 million.
The company disclosed an ongoing SEC investigation regarding prostate cancer therapeutic candidates development disclosures, though this doesn't affect commercial products. Telix continues expanding globally with multiple regulatory approvals and advances across its therapeutic pipeline.
Telix Pharmaceuticals (NASDAQ: TLX) has achieved a significant milestone as its prostate cancer imaging agent Gozellix received a permanent Healthcare Common Procedure Coding System (HCPCS) code from CMS. The code A9616, effective October 1, 2025, will facilitate provider billing and reimbursement processes.
Gozellix is a PSMA PET imaging agent used for detecting prostate cancer metastasis in initial therapy candidates and patients with suspected biochemical recurrence. The product features an extended shelf-life and flexible production options, addressing historical logistical barriers in PSMA-PET imaging access.
The HCPCS code represents a crucial step toward obtaining Transitional Pass-Through payment status and expanding commercial accessibility of PSMA PET imaging across the United States.